UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 419

Sortiert nach

Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity

Journal of thrombosis and haemostasis, 2004-10, Vol.2 (10), p.1700-1708

Aledort, L. M.

2004

Volltextzugriff (PDF)

Can B‐domain deletion alter the immunogenicity of recombinant factor VIII? A meta‐analysis of prospective clinical studies

Journal of thrombosis and haemostasis, 2011-11, Vol.9 (11), p.2180-2192

2011

Volltextzugriff (PDF)

Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis

Thrombosis and haemostasis, 2001-03, Vol.85 (3), p.560

2001

Volltextzugriff (PDF)

Factor VIII inhibitor bypassing activity (FEIBA) - addressing safety issues

Haemophilia : the official journal of the World Federation of Hemophilia, 2008-01, Vol.14 (1), p.39-43

ALEDORT, L. M.

2008

Volltextzugriff (PDF)

Harmonization of clinical trial guidelines for assessing the risk of inhibitor development in hemophilia A treatment

Journal of thrombosis and haemostasis, 2011-03, Vol.9 (3), p.423-427

ALEDORT, L. M.

2011

Volltextzugriff (PDF)

The effect of a specialized case management programme on the cost of factor replacement use in patients with bleeding disorders

Haemophilia : the official journal of the World Federation of Hemophilia, 2014-05, Vol.20 (3), p.e240-e242

Aledort, L. M.

2014

Volltextzugriff (PDF)

Evaluation of bleeding and thrombotic events during long‐term use of romiplostim in patients with chronic immune thrombocytopenia (ITP)

Journal of thrombosis and haemostasis, 2010-06, Vol.8 (6), p.1372-1382

2010

Volltextzugriff (PDF)

Glanzmann's thrombasthenia: meeting the anticoagulation challenge

Haemophilia : the official journal of the World Federation of Hemophilia, 2015-07, Vol.21 (4), p.e322-e323

2015

Volltextzugriff (PDF)

Adult, previously untreated patients remain a significant therapeutic challenge

Journal of thrombosis and haemostasis, 2016-10, Vol.14 (10), p.2075-2076

2016

Volltextzugriff (PDF)

Why should we care about quality of life in persons with haemophilia?

Haemophilia : the official journal of the World Federation of Hemophilia, 2012-05, Vol.18 (3), p.e154-e157

2012

Volltextzugriff (PDF)

An International Prophylaxis Study Group (IPSG) survey of prophylaxis in adults with severe haemophilia

Haemophilia : the official journal of the World Federation of Hemophilia, 2017-09, Vol.23 (5), p.e447-e450

2017

Volltextzugriff (PDF)

Tertiary prophylaxis in adults: is there a rationale?

Haemophilia : the official journal of the World Federation of Hemophilia, 2012-09, Vol.18 (5), p.722-728

2012

Volltextzugriff (PDF)

Prophylaxis re‐visited: The potential impact of novel factor and non‐factor therapies on prophylaxis

Haemophilia : the official journal of the World Federation of Hemophilia, 2018-11, Vol.24 (6), p.845-848

2018

Volltextzugriff (PDF)

Early platelet activation, inflammation and acute brain injury after a subarachnoid hemorrhage: a pilot study

Journal of thrombosis and haemostasis, 2012-04, Vol.10 (4), p.711-713

2012

Volltextzugriff (PDF)

Idiopathic thrombocytopenic purpura : A practice guideline developed by explicit methods for the American Society of Hematology

Blood, 1996-07, Vol.88 (1), p.3-40

1996

Volltextzugriff (PDF)

An International Prophylaxis Study Group (IPSG) survey of prophylaxis in inhibitor positive children/adults with severe haemophilia

Haemophilia : the official journal of the World Federation of Hemophilia, 2017-09, Vol.23 (5), p.e444-e447

2017

Volltextzugriff (PDF)

Primary and rescue immune tolerance induction in children and adults: a multicentre international study with a VWF-containing plasma-derived FVIII concentrate

Haemophilia : the official journal of the World Federation of Hemophilia, 2014-01, Vol.20 (1), p.83-91

2014

Volltextzugriff (PDF)

Another role for the VW molecule

Haemophilia : the official journal of the World Federation of Hemophilia, 2012-03, Vol.18 (2), p.246-247

ALEDORT, L. M.

2012

Volltextzugriff (PDF)

Is the incidence and prevalence of inhibitors greater with recombinant products? Yes

Journal of thrombosis and haemostasis, 2004-06, Vol.2 (6), p.861-862

Aledort, L. M.

2004

Volltextzugriff (PDF)

The EPIC study: a lesson to learn

Haemophilia : the official journal of the World Federation of Hemophilia, 2015-09, Vol.21 (5), p.622-628

2015

Volltextzugriff (PDF)

Efficacy of factor VIII/von Willebrand factor concentrate Alphanate® in preventing excessive bleeding during surgery in subjects with von Willebrand disease

Haemophilia : the official journal of the World Federation of Hemophilia, 2008-03, Vol.14 (2), p.271-275

2008

Volltextzugriff (PDF)

Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors

Thrombosis and haemostasis, 1998-12, Vol.80 (6), p.912

1998

Volltextzugriff (PDF)

The use of a single von Willebrand factor‐containing, plasma‐derived FVIII product in hemophilia A immune tolerance induction: the US experience

Journal of thrombosis and haemostasis, 2011-11, Vol.9 (11), p.2229-2234

2011

Volltextzugriff (PDF)

Best evidence on B‐domain deletion and the immunogenicity of recombinant factor VIII

Journal of thrombosis and haemostasis, 2011-11, Vol.9 (11), p.2325-2327

2011

Volltextzugriff (PDF)

To bleed or not to bleed – is that a question?

Journal of thrombosis and haemostasis, 2010-01, Vol.8 (1), p.81-82

ALEDORT, L. M.

2010

Volltextzugriff (PDF)

1 – 25 von 419

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(384)
Mit Volltextzugriff
(283)

Publikationsform

Sprache

Englisch
(419)
Japanisch
(13)

Erscheinungsjahr

n.n

Thema

Humans
(282)
Science & Technology
(243)
Life Sciences & Biomedicine
(240)
Hematology
(159)
Adult
(102)
Male
(101)
Biological And Medical Sciences
(89)
Medical Sciences
(87)
Female
(62)
Middle Aged
(62)
Hemophilia A - Complications
(59)
Child
(56)
Hemophilia A - Drug Therapy
(53)
Adolescent
(52)
Factor Viii - Therapeutic Use
(52)
Hemophilia A - Therapy
(52)
Cardiovascular System & Cardiology
(45)
Aids/hiv
(43)
Hematologic And Hematopoietic Diseases
(42)
Hemophilia A - Immunology
(39)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity

Can B‐domain deletion alter the immunogenicity of recombinant factor VIII? A meta‐analysis of prospective clinical studies

Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis

Factor VIII inhibitor bypassing activity (FEIBA) - addressing safety issues

Harmonization of clinical trial guidelines for assessing the risk of inhibitor development in hemophilia A treatment

The effect of a specialized case management programme on the cost of factor replacement use in patients with bleeding disorders

Evaluation of bleeding and thrombotic events during long‐term use of romiplostim in patients with chronic immune thrombocytopenia (ITP)

Glanzmann's thrombasthenia: meeting the anticoagulation challenge

Adult, previously untreated patients remain a significant therapeutic challenge

Why should we care about quality of life in persons with haemophilia?

An International Prophylaxis Study Group (IPSG) survey of prophylaxis in adults with severe haemophilia

Tertiary prophylaxis in adults: is there a rationale?

Prophylaxis re‐visited: The potential impact of novel factor and non‐factor therapies on prophylaxis

Early platelet activation, inflammation and acute brain injury after a subarachnoid hemorrhage: a pilot study

Idiopathic thrombocytopenic purpura : A practice guideline developed by explicit methods for the American Society of Hematology

An International Prophylaxis Study Group (IPSG) survey of prophylaxis in inhibitor positive children/adults with severe haemophilia

Primary and rescue immune tolerance induction in children and adults: a multicentre international study with a VWF-containing plasma-derived FVIII concentrate

Another role for the VW molecule

Is the incidence and prevalence of inhibitors greater with recombinant products? Yes

The EPIC study: a lesson to learn

Efficacy of factor VIII/von Willebrand factor concentrate Alphanate® in preventing excessive bleeding during surgery in subjects with von Willebrand disease

Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors

The use of a single von Willebrand factor‐containing, plasma‐derived FVIII product in hemophilia A immune tolerance induction: the US experience

Best evidence on B‐domain deletion and the immunogenicity of recombinant factor VIII

To bleed or not to bleed – is that a question?

Suchergebnisse filtern